▲ AI PRISM* Personalized Economic Briefing
* Editor's note: AI PRISM (Personalized Report & Insight Summarizing Media) is an AI-based personalized news recommendation and summary service developed with support from the Korea Press Foundation. It selects and provides six news items tailored to each reader type.
[Key Issue Briefing]
■ The interest-free loan bill: France has widened eligibility for its interest-free mortgage program, known as PTZ, to smaller provincial cities and households with children, driving up both the number of loans and the tax burden. Politicians there are warning that a loan that costs the borrower nothing still costs the taxpayer.
■ Cancer vaccine falls short of hopes: A personalized messenger RNA cancer vaccine jointly developed by Moderna and Merck showed it reduced the risk of recurrence and death in a Phase 3 trial. But the figures came in below earlier Phase 2 results, sending shares sharply lower, with analysts concluding that the problem was overheated expectations rather than the treatment itself.
■ Tech blockade and funding squeeze: Even as it extends a trade truce, the U.S. is keeping up its technological pushback by blocking Chinese investment in security-related fields such as AI and biotechnology. Meanwhile, Big Tech's AI capital spending has outpaced its own cash generation, shifting the center of gravity in the technology race toward a contest over funding.
[News of Interest to Global Investors]
- Key summary: France's expansion of its interest-free mortgage program (PTZ) has turned into a dispute over fiscal costs. The PTZ is a supplementary loan that must be used alongside a conventional mortgage. The average loan amount in the fourth quarter of last year was 56,803 euros (about 84.4 million won), and borrowers can take out up to 50% of the purchase cost for a newly built apartment, or as much as 180,000 euros. After eligibility was broadened to smaller provincial cities in April last year, the number of loans rose to 72,906 last year from 44,466 in 2024 and is estimated to reach 82,900 this year, with tax credits disbursed this year amounting to 930 million euros. With the International Monetary Fund projecting France's debt-to-GDP ratio at 118.5% this year, experts say Korea — where debate continues over a basic finance proposal to lend every citizen 10 million won at low interest — should treat the French case as a cautionary example.
2. Moderna Cancer Vaccine Succeeds in Phase 3 but Falls Short of Wall Street's Bar
- Key summary: Intismeran, the personalized mRNA cancer vaccine Moderna and Merck are jointly developing, demonstrated therapeutic benefit in a Phase 3 trial, yet the shares plunged. Patients who received the vaccine together with Merck's immunotherapy Keytruda had a 42% lower risk of cancer recurrence or death than those given Keytruda alone, below the 49% recorded in a smaller Phase 2 study. The trial enrolled 1,137 patients with high-risk stage 2B to stage 4 melanoma whose cancer had been surgically removed, with a median follow-up of 24.6 months and a hazard ratio — the instantaneous risk of recurrence or death — of 0.58. Moderna closed down 17.57% at $202.63 on the New York market on the 22nd, and Wall Street assessed that the decline reflected excessively high expectations for the trial results rather than any shortcoming in efficacy.
3. U.S. Blocks Chinese Investment in AI, Biotech as Tech Blockade Outlasts Trade Truce
- Key summary: The U.S. is imposing strict limits on Chinese investment in technologies that affect national security, including artificial intelligence and biotechnology. The Treasury Department on the 22nd released implementing rules for a comprehensive outbound investment national security law passed by Congress last year, placing Chinese investment in AI fields including advanced semiconductors, brain-computer interfaces and biotechnology-related compounds under regulation. The step came a month after U.S. President Donald Trump and Chinese President Xi Jinping extended their trade truce to January next year at a summit in Washington, D.C., last month. Estimates have also emerged that the Pentagon secretly established a Technology Support Office in April to impede adversaries' development of advanced military technology, with classified contract spending alone expected to exceed $1.5 billion (about 2 trillion won).
- Key summary: Big Tech's AI investment has outgrown its ability to fund itself, turning the race into a battle over capital. Combined capital expenditures at five companies — Microsoft, Alphabet, Amazon, Meta and Oracle — are projected to total $945.55 billion by January next year, roughly six times the level of January 2023, while their free cash flow over the same period is expected to swing to negative $2.87 billion from $223.11 billion. After Meta disclosed AI infrastructure commitments of $825 billion (about 1,100 trillion won), including leases and cloud contracts, its credit default swap premium — the cost of derivatives that hedge against default — jumped to 119.3 basis points. Anthropic and OpenAI each plan to press ahead with initial public offerings next month. Nvidia Chief Executive Jensen Huang stressed that the obstacle to expanding AI investment is funding rather than weak demand, and the industry is read as pinning hopes on private market capital and expanded U.S. government support for data centers.
